Autopsy report · NCT00985907

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

“Low Accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 years 11 months after it had already started.
• Ran for about 5 years 2 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 10 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

University of California, San Francisco

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma; Patient Participation

Interventions

Doxil, melphalan, bortezomib

Participants

13

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.